Navigation Links
Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
Date:5/6/2008

MELVILLE, N.Y., May 6 /PRNewswire/ -- Today, Fougera, a division of Nycomed US Inc., announced it has received FDA approval to bring to market the first generic Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution). The generic formulation compares to Dovonex(R) by Warner-Chilcott.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080506/NYTU034 )

Fougera's Calcipotriene Topical Solution is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp (see product package insert for full prescribing information). It is available in a 60 mL bottle (NDC # 0168-0400-60).

"Fougera has received more FDA approvals for topical products during the past seven years than any other generic company. Today's announcement that we are first-to-market with Calcipotriene Topical Solution is another example of our ongoing commitment to provide safe, effective and affordable options to health care providers and their patients," stated David Klaum, Senior Vice President, Commercial Business Operations.

Founded in 1849, Fougera is the largest of the three Nycomed US Inc. divisions and is the leading manufacturer and distributor of a wide range of topical steroids, antibiotics and antifungal products. For more information on Fougera's complete line of products, please call Fougera Customer Service at (800) 645-9833 or visit the company online at http://www.fougera.com.

About Nycomed US

Nycomed US, Inc. (formerly ALTANA Inc) is a subsidiary of Nycomed, and also operates two additional divisions in the US focused on specialty pharmaceuticals in dermatology. The PharmaDerm(R) division of Nycomed is dedicated to bringing innovative products to the dermatologists so they can best care for their patients. Nycomed US, Inc. and its PharmaDerm Division recently announced the acquisition of Bradley Pharmaceuticals, a global specialty company with 3 divisions-Doak Dermatologics, Kenwood Therapeutics, and A. Aarons. The Bradley product line will be combined with the current offerings of PharmaDerm, enabling the Company to offer more therapeutic choices and enhanced customer service. Combined with Nycomed's Fougera Division, Nycomed becomes a leader in the dermatology market. Nycomed US also markets and sells Savage Laboratories products, which focus on emergency care.


'/>"/>
SOURCE Fougera
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. Topical Cream Treats Precancerous Lesions of Vulva
3. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
4. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
5. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
6. Topical treatment for age spots, from Harvard Womens Health Watch
7. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
8. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
9. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
10. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
11. UHW Outlines Solutions to Californias Health Crisis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could ... after surgery, though activity levels decline over time. The study, presented today at ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and application ... arm of one of world’s largest healthcare services providers. , According to ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... In vitro diagnostics market firm Kalorama Information ... least ten diagnostic companies have successfully completed financings.  The ... a loan facility.  The size of these financings ranged ... Information provides a monthly IVD Market Trends Report ... "Diagnostics deals ...
Breaking Medicine Technology: